| 1. |
Tonon CR, Silva TAAL, Pereira FWL, et al. A review of current clinical concepts in the pathophysiology, etiology, diagnosis, and management of hypercalcemia. Med Sci Monit, 2022, 28: e935821.
|
| 2. |
Motlaghzadeh Y, Bilezikian JP, Sellmeyer DE. Rare causes of hypercalcemia: 2021 update. J Clin Endocrinol Metab, 2021, 106(11): 3113-3312.
|
| 3. |
Banu S, Batool S, Sattar S, et al. Malignant and non-malignant causes of hypercalcemia: a retrospective study at a tertiary care hospital in Pakistan. Cureus, 2021, 13(6): e15845.
|
| 4. |
Dandurand K, Ali DS, Khan AA. Primary hyperparathyroidism: a narrative review of diagnosis and medical management. J Clin Med, 2021, 10(8): 1604.
|
| 5. |
Gonciulea AR, Wang Y, Bikle DD, et al. Hypercalcemia in non-Hodgkin’s lymphoma due to cosecretion of PTHrP and 1, 25-dihydroxyvitamin D. Osteoporos Int, 2021, 32(12): 2587-2592.
|
| 6. |
Umer M, Mohib Y, Atif M, et al. Skeletal metastasis in renal cell carcinoma: a review. Ann Med Surg (Lond), 2018, 27: 9-16.
|
| 7. |
Gomes Lda S, Kulak CA, Costa TM, et al. Association of primary hyperparathyroidism and humoral hypercalcemia of malignancy in a patient with clear cell renal carcinoma. Arch Endocrinol Metab, 2015, 59(1): 84-88.
|
| 8. |
Turner JJO. Hypercalcaemia – presentation and management. Clin Med (Lond), 2017, 17(3): 270-273.
|
| 9. |
中華醫學會骨質疏松和骨礦鹽疾病分會, 中華醫學會內分泌分會代謝性骨病學組. 原發性甲狀旁腺功能亢進癥診療指南. 中華骨質疏松和骨礦鹽疾病雜志, 2014, 7(3): 187-198.
|
| 10. |
Law IP, Blom J. Second malignancies in patients with multiple myeloma. Oncology, 1977, 34(1): 20-24.
|
| 11. |
Chisholm RC, Weaver YJ, Chung EB, et al. Coexistent multiple myeloma and parathyroid adenoma. JAMA, 1982, 248(1): 33.
|
| 12. |
Wong KK, Harris JR. Parathyroid adenoma presenting as paraneoplastic syndrome secondary to renal cell carcinoma. J Otolaryngol, 2005, 34(4): 280-281.
|
